journal
Journals Expert Review of Anticancer Th...

Expert Review of Anticancer Therapy

https://read.qxmd.com/read/38993050/the-new-life-of-ibrutinib-therapy-in-cll-enhancing-personalized-approaches
#1
EDITORIAL
Stefano Molica, Francesca Romana Mauro
No abstract text is available yet for this article.
July 12, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38990648/immune-related-adverse-events-associated-with-mogamulizumab-a-comprehensive-review-of-the-literature
#2
REVIEW
Genevieve S Silva, Ellen J Kim, Stefan K Barta, Jina Chung
INTRODUCTION: Mogamulizumab is an anti-C-C chemokine receptor 4 antibody that is increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma, adult T-cell leukemia-lymphoma, and peripheral T-cell lymphoma. Because CCR4 is expressed on both malignant T-cells and regulatory T-cells (Tregs), mogamulizumab can be associated with increased immune-related adverse events (irAEs). While there is abundant literature on mogamulizumab-associated rash (MAR) and graft-versus-host disease (GVHD), other reported irAEs have not been collated into a single review...
July 11, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38989818/elevated-dkk1-expression-a-promising-prognostic-biomarker-and-therapeutic-target-in-head-and-neck-squamous-cell-carcinoma
#3
JOURNAL ARTICLE
Waseem Jerjes
No abstract text is available yet for this article.
July 11, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38975629/screening-of-genes-related-to-programmed-cell-death-in-esophageal-squamous-cell-carcinoma-and-construction-of-prognostic-model-based-on-transcriptome-analysis
#4
JOURNAL ARTICLE
Min Chen, Yijun Qi, Shenghua Zhang, Yubo Du, Haodong Cheng, Shegan Gao
OBJECTIVES: To screen programmed cell death (PCD)-related genes in esophageal squamous cell carcinoma (ESCC) based on transcriptomic data and to explore its clinical value. METHODS: Differentially expressed PCD genes (DEPCDGs) were screened from ESCC transcriptome and clinical data in TCGA database. Univariate COX and LASSO COX were performed to on prognostically DEPCDGs in ESCC to develop prognostic model. Differences in immune cell infiltration in different RiskScore groups were determined by ssGSEA and CIBERSORT...
July 8, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38970210/evaluating-the-efficacy-and-safety-of-trebananib-in-treating-ovarian-cancer-and-non-ovarian-cancer-patients-a-meta-analysis-and-systematic-review
#5
REVIEW
Jialin Zhang, Jingyang Su, Yeyue Zhou, Jinhua Lu
OBJECTIVES: Due to its anti-angiogenic properties, trebananib is frequently employed in the treatment of cancer patients, particularly those with ovarian cancer. We conducted a meta-analysis to assess the efficacy and safety profile of trebananib in combination with other drugs for treating both ovarian and non-ovarian cancer patients. METHODS: Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5...
July 5, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38946484/first-in-human-clinical-trial-results-with-abbv-184-a-first-in-class-t-cell-receptor-anti-cd3-bispecific-protein-in-adults-with-previously-treated-aml-or-nsclc
#6
JOURNAL ARTICLE
Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, Abraham Avigdor, Toshio Shimizu
BACKGROUND: ABBV-184, a novel survivin peptide-targeting T-cell receptor (TCR)/anti-CD3 bispecific protein, demonstrated preclinical T-cell activation and cytotoxicity toward HLA-A2:01-positive tumor lines. This first-in-human trial evaluated ABBV-184 monotherapy in patients with acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC). RESEARCH DESIGN AND METHODS: This phase 1 multicenter, open-label, dose escalation trial (NCT04272203) enrolled adult patients with relapsed/refractory AML or NSCLC with an HLA-A2:01 restricted genotype...
July 1, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38932631/highlights-from-the-2024-asco-genitourinary-symposium-focus-on-urothelial-and-prostate-cancer
#7
JOURNAL ARTICLE
Alessandro Strusi, Giada Pinterpe, Chiara Ciccarese, Romina Rose Pedone, Michele Sarcina, Valeria Sardaro, Rachele Belletto, Angelo Totaro, Marco Racioppi, Rossana Berardi, Giampaolo Tortora, Roberto Iacovelli
The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting. In PC, adjuvant therapy with high-dose radiotherapy schedules plus long-t erm ADT was explored. In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments...
June 27, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38912860/2024-asco-genitourinary-cancers-symposium-a-focus-on-renal-cell-carcinoma
#8
JOURNAL ARTICLE
Viria Beccia, Daniela Arduini, Roberto Iacovelli, Alessandro Scala, Denis Occhipinti, Chiara Ligato, Luigi Roca, Pierluigi Russo, Nazario Foschi, Giampaolo Tortora, Chiara Ciccarese
In this article, we report the breakthrough acquisitions for renal cell carcinoma (RCC) management presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. The results from Keynote 564 showed an impressive overall survival (OS) advantage for pembrolizumab, in patients at higher risk of relapse after surgery and confirmed the benefit in terms of disease-free survival (DFS). Until now, pembrolizumab is the only immune checkpoint inhibitor (ICI) to prove a survival advantage...
June 27, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38912754/augmenting-the-landscape-of-chimeric-antigen-receptor-t-cell-therapy
#9
REVIEW
Shalini Srivastava, Sanjay Singh, Ajay Singh
INTRODUCTION: The inception of recombinant DNA technology and live cell genomic alteration have paved the path for the excellence of cell and gene therapies and often provided the first curative treatment for many indications. The approval of the first Chimeric Antigen Receptor (CAR) T-cell therapy was one of the breakthrough innovations that became the headline in 2017. Currently, the therapy is primarily restricted to a few nations, and the market is growing at a CAGR (current annual growth rate) of 11...
June 26, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38913911/multitargeted-polypharmacotherapy-for-cancer-treatment-theoretical-concepts-and-proposals
#10
JOURNAL ARTICLE
Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Borstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui
INTRODUCTION: . The pharmacological treatment of cancer has evolved from cytotoxic to molecular targeted therapy. The median survival gains of 124 drugs approved by the FDA from 2003 to 2021 is 2.8 months. Targeted therapy is based on the somatic mutation theory, which has some paradoxes and limitations. While efforts of targeted therapy must continue, we must study newer approaches that could advance therapy and affordability for patients. AREAS COVERED: This work briefly overviews how cancer therapy has evolved from cytotoxic chemotherapy to current molecular-targeted therapy...
June 24, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38913791/treatment-options-in-the-advanced-and-recurrent-setting-for-endometrial-cancer-an-update
#11
REVIEW
Alex Andrea Francoeur, Virginia Fontenont, Krishnansu Sujata Tewari
INTRODUCTION: Uterine cancer is the most common gynecologic malignancy in women and is projected to surpass ovarian cancer as the deadliest gynecologic malignancy in the United States in 2024. Additionally, rates of advanced and high-risk uterine cancer have been on the rise in the United States, demonstrating a need for innovation in treatment options. There have been multiple recent trials investigating the incorporation of novel agents in the treatment of advanced and recurrent endometrial cancer...
June 24, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38913581/current-practices-in-oncofertility-counseling-updated-evidence-on-fertility-preservation-and-post-treatment-pregnancies-in-young-women-affected-by-early-breast-cancer
#12
REVIEW
Luca Arecco, Roberto Borea, Isotta Martha Magaton, Kristina Janković, Elene Mariamizde, Mihaela Stana, Graziana Scavone, Silvia Ottonello, Stefano Spinaci, Carlo Genova, Evandro de Azambuja, Matteo Lambertini
INTRODUCTION: Anticancer treatments have significantly contributed to increasing cure rates of breast cancer in the last years; however, they can also lead to medium- and long-term side effects, including gonadotoxicity and compromised fertility in young women. Oncofertility is a crucial issue for young patients who have not yet completed their family planning at the time of cancer diagnosis. AREAS COVERED: This review aims to cover all the latest available evidence in the field of oncofertility, including the gonadotoxicity of currently adopted anticancer therapies in the curative breast cancer setting, the available strategies for fertility preservation and the feasibility of achieving a pregnancy following anticancer treatments completion...
June 24, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38907661/risks-and-benefits-of-sentinel-lymph-node-evaluation-in-the-management-of-endometrial-intraepithelial-neoplasia
#13
REVIEW
Lauren M Lim, Hadi Erfani, Katelyn B Furey, Koji Matsuo, X Mona Guo
INTRODUCTION: Endometroid intraepithelial neoplasia (EIN) is a premalignant lesion to endometrial cancer. Increasing number of gynecologic oncologists are performing sentinel lymph node (SLN) evaluation during hysterectomy for EIN to ensure complete staging if there is cancer on the final specimen. However, there are no clear guidelines and the benefits and risks to performing SLN evaluation for EIN patients are unclear. AREAS COVERED: This narrative review examines the advantages and disadvantages of SLN evaluation for EIN patients and provides an algorithm to assist clinicians in selectively applying the procedure for maximal patient benefit...
June 22, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38879826/the-incidence-and-relative-risk-of-major-adverse-cardiovascular-events-and-hypertension-in-patients-treated-with-immune-checkpoint-inhibitors-plus-tyrosine-kinase-inhibitors-for-solid-tumors-a-systemic-review-and-meta-analysis
#14
REVIEW
Chiara Ciccarese, Annunziato Anghelone, Alessio Stefani, Antonio Cigliola, Alessandro Strusi, Filippo D'Agostino, Emilio Bria, Roberto Iacovelli, Giampaolo Tortora
INTRODUCTION: Combinations of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) can be responsible for major adverse cardiovascular events (MACEs). We performed a meta-analysis to assess the relative risk (RR) of MACEs and hypertension in cancer patients treated with ICI+TKI combinations. RESEARCH DESIGN AND METHODS: We selected prospective trials through MEDLINE/PubMed, Cochrane Library, and ASCOMeeting abstracts. We calculated combined ORs, RRs, and 95% CIs using RevMansoftware for meta-analysis (v...
June 16, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38874538/nomogram-and-calculator-for-predicting-the-prognosis-of-patients-with-giant-hepatocellular-carcinoma
#15
JOURNAL ARTICLE
Wanjin Chen, Shengtao Cheng
OBJECTIVES: This study aimed to explore the factors affecting the overall survival (OS) of giant hepatocellular carcinoma (G-HCC) patients and establish a nomogram and an Internet-based OS calculator for evaluating the OS of G-HCC patients. RESEARCH DESIGN AND METHODS: A total of 2445 G-HCC patients were searched in the SEER database. The independent variables affecting OS of G-HCC patients were determined by univariate and multivariate analyses, and a nomogram and Internet-based OS calculator were established...
June 14, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38863432/immunotherapy-in-mmr-d-msi-h-recurrent-metastatic-endometrial-cancer
#16
REVIEW
Renata Pacholczak-Madej, Michele Bartoletti, Lucia Musacchio, Mirosława Püsküllüoglu, Paweł Blecharz, Domenica Lorusso
INTRODUCTION: The advent of immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the management of mismatch repair deficient (MMR-d)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Initially investigated as monotherapy in phase I-II clinical trials for recurrent disease, immunotherapy demonstrated remarkable activity, yielding overall response rates (ORR) ranging from 27% to 58%. Based on these promising findings, phase III trials have explored the integration of immunotherapy into first-line treatment regimens for advanced/recurrent EC in combination with chemotherapy or other agents such as tyrosine kinase inhibitors (TKIs), resulting in improved ORR, progression-free survival, and overall survival compared to the standard chemotherapy regimen of paclitaxel and carboplatin...
June 12, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38861580/relacorilant-in-recurrent-ovarian-cancer-clinical-evidence-and-future-perspectives
#17
REVIEW
Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy, Anna Fagotti, Giovanni Scambia, Claudia Marchetti
INTRODUCTION: Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting. AREAS COVERED: Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed...
June 11, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38855809/is-ctdna-ready-to-outpace-imaging-in-monitoring-early-and-advanced-breast-cancer
#18
JOURNAL ARTICLE
Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, Elisabetta Molteni, Linda Cucciniello, Lucia Da Ros, Silvia Buriolla, Lorenzo Cereser, Rossana Roncato, Lorenzo Gerratana, Fabio Puglisi
INTRODUCTION: circulating tumor DNA (ctDNA) and radiological imaging are increasingly recognized as crucial elements in breast cancer management. While radiology remains the cornerstone for screening and monitoring, ctDNA holds distinctive advantages in anticipating diagnosis, recurrence or progression, providing concurrent biological insights complementary to imaging results. AREAS COVERED: this review delves into the current evidence on the synergistic relationship between ctDNA and imaging in breast cancer...
June 10, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38832770/adenoid-cystic-carcinoma-of-minor-salivary-glands-adccmsg-a-multidisciplinary-update
#19
REVIEW
Rebecca Romanò, Francesca De Felice, Andrea Ferri, Marco Della Monaca, Roberto Maroldi, Lisa Licitra, Laura Deborah Locati, Salvatore Alfieri
INTRODUCTION: Adenoid cystic carcinoma of minor salivary glands (AdCCmSG) represents a 'rarity in the rarity,' posing a clinical challenge in lack of standardized, evidence-based recommendations. At present, AdCCmSG management is mostly translated from major salivary gland cancers (MSGCs). Ideally, AdCCmSG diagnostic-therapeutic workup should be discussed and carried out within a multidisciplinary, high-expertise setting, including pathologists, surgeons, radiation oncologists and medical oncologists...
June 4, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38813930/first-line-concomitant-egfr-tki-chemotherapy-versus-egfr-tki-alone-for-advanced-egfr-mutated-nsclc-a-meta-analysis-of-randomized-phase-iii-trials
#20
REVIEW
Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Chouaïd
INTRODUCTION: A tyrosine-kinase inhibitor (TKI) is indicated as a first-line treatment for patients with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor - receptor ( EGFR ) mutation. Chemotherapy (ChT) given in combination with an EGFR-TKI in this setting is of interest. METHODS: We conducted a meta-analysis of phase III randomized trials comparing EGFR-TKI + ChT vs. EGFR-TKI alone as first-line therapy for advanced NSCLC harboring an activating EGFR mutation...
June 3, 2024: Expert Review of Anticancer Therapy
journal
journal
39793
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.